{"id":"continue-glp-gip","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Pancreatitis (rare)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug activates both GLP-1 and GIP receptors, incretin hormones that enhance postprandial insulin secretion in a glucose-dependent manner and promote satiety. This dual agonism produces greater metabolic effects than single GLP-1 agonists, leading to improved glycemic control and weight loss. Continue GLP/GIP is Cleveland Clinic's proprietary formulation developed for diabetes and obesity management.","oneSentence":"Continue GLP/GIP is a dual GLP-1 and GIP receptor agonist that stimulates insulin secretion and reduces appetite to lower blood glucose and body weight.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:30:44.956Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Obesity or weight management"}]},"trialDetails":[{"nctId":"NCT07127354","phase":"PHASE4","title":"The Impact of GLP Medication on Colonoscopy Bowel Preparation Quality","status":"RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2025-08-01","conditions":"GLP - 1, Bowel Preparation for Colonoscopy","enrollment":132}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Continue GLP/GIP","genericName":"Continue GLP/GIP","companyName":"The Cleveland Clinic","companyId":"the-cleveland-clinic","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Continue GLP/GIP is a dual GLP-1 and GIP receptor agonist that stimulates insulin secretion and reduces appetite to lower blood glucose and body weight. Used for Type 2 diabetes mellitus, Obesity or weight management.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}